Pulmonary delivery of anti-microbial peptides (AMP’s): disposition within ex-vivo and in-vivo lung models
Introduction
Mark Gumbleton and Research Fellow Dr Chris Morris are extending their collaboration with dstl (Defence Science and Technology Laboratory) to further develop anti-microbial peptides (AMP) for delivery to the lung.
Aims of Project
To assess the tissue distribution of AMPs delivered to intact lung models and to evaluate changes in the profile of pulmonary cytokines and enzymes in response to AMP delivery. the project will involve the study of AMP pharmacokinetics upon the delivery of nanoÿ and microparticulate AMP formulations to ex-vivo and in-vivo lung models.
Funder
Defence Science and Technology Laboratory
Project Value
£99,599
Duration
1 year
Dr Mark Gumbleton
Position:Reader and Director of Research
Email: gumbleton@cf.ac.ukTelephone: +44 (0)29 208 75449